Getting caught up in quarter-to-quarter revenue timing issues in the context of an early-stage, rapidly growing global business really is missing the point. Agree with Access2020 re management. Once again they have failed in their communications with the market by reconfirming guidance so late in the period and then subsequently missing. I think that is the biggest issue right now, not anything operational.
- Forums
- ASX - By Stock
- Ann: Business Update
Getting caught up in quarter-to-quarter revenue timing issues in...
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PET (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.60M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
PET (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online